Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03330678
Other study ID # 2012-70-EMP-61
Secondary ID
Status Completed
Phase N/A
First received October 26, 2017
Last updated October 30, 2017
Start date December 2013
Est. completion date December 2015

Study information

Verified date October 2017
Source Sanjay Gandhi Postgraduate Institute of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Healthy human gut contains a large number of bacteria, which belong to several different species. Some genes in these bacteria encode enzymes that the human body cannot produce. These enzymes can catalyze metabolic reactions in the distal small bowel. For instance, bacterial enzymes can breakdown indigestible dietary constituents, making available extra energy to the host. The current paradigm treats the human body as a 'metagenome', i.e. a composite of Homo sapiens genes and genes in the genomes of the colonizing bacteria.

Till recently, accurate determination of bacterial gut flora was not possible. Recent development of multi-parallel sequencing techniques has allowed unbiased determination of profile of gut flora. These techniques have revealed changes in gut flora in several disease conditions, including those of the gastrointestinal tract and liver. This has prompted the use of drugs, such as probiotics to restore the gut flora.

Probiotics contain living microorganisms, and are administered in an attempt to obtain health benefits by restoring normal gut flora. These preparations provide benefit to patients with several diseases, including childhood diarrhea, antibiotic-associated diarrhea, inflammatory bowel disease, vaginitis, etc. However, the mechanisms of their beneficial effects remains unclear. Gut microbiota appear to modulate the development of immune system and maintain a balance between Th17 and T regulatory cells in animals. However, it is not known whether administration of probiotics changes the profile (nature and relative density of various species) of gut flora, and whether these changes are short-lasted or persistent.

This proposal aimed to study whether probiotic administration influences the gut bacterial profile and host immune responses. In addition, we wished to determine whether the changes in gut flora and immune responses persist after probiotic administration is stopped.


Description:

Study Subjects The study included 14 healthy non-pregnant women. All subjects provided a written informed consent. The subjects had to (i) be free of systemic (diabetes, autoimmune disease, cancer), gastrointestinal or liver diseases that are known to be associated with alterations in intestinal flora, (ii) be non-obese (body mass index in the range of 20 to 25 Kg/m2), and (iii) not have taken any anti-microbial agent, probiotics, gastric acid suppressant drugs or drugs that alter gastrointestinal motility, in the previous 6 weeks.

Study design Each subject was studied at 3 time points: (i) baseline (enrolment), (ii) after administration of a probiotic in usual dose for four weeks, and (iii) four weeks after discontinuation of probiotic administration. Each subject received Cap VSL#3, 2 capsules daily (each capsule contains 112.5 billion bacteria -- a mixture of 8 bacteria -- Streptococcus thermophilus, Bifido-bacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii). At each time point, gut microbiota profile and immune responses were studied.

Metagenomic study for analysis of gut flora Analysis for identification and profiling of gut microflora was done using sequencing of V3 region of the 16S ribosomal ribonucleic acid gene. This gene contains nine variable regions flanked by conserved stretches in all bacteria. Amplification and sequencing of any hypervariable region using specific primers can be used to determine the nature of the bacterium (phylum, family, genus, species, etc). The most widely used regions are V3, V4 and V6; we used V3 region, due to its higher taxonomic resolution.

Stool specimen were collected from subjects at 3 time points as indicated above by asking the subject to pass stool into a clean sterile receptacle; the receptacle was immediately frozen and transported to the laboratory. DNA was isolated from each specimen using standard protocols, quantified, normalised and stored frozen until further use.

Polymerase chain reaction amplification of V3 region was done. Gel-purified amplicons (with different adapter sequences so that data for each sample can be separated at analysis stage) were quantified, normalised and pooled in equimolar quantities (multiplexing). The multiplexed library was subjected to quality control using an Agilent Bioanalyser DNA Chip.

The sequencing library containing V3 amplicons from an equi-amount mixture of various clinical samples was sequenced using an Illumina machine in both directions. The sequence reads were binned according to index sequences, subjected to quality control and sequences in the two directions were fused together to obtain a single read. The sequence data were analysed to determine the profile of gut flora.

Immunological studies Collection of blood specimens Venous blood (6 ml) was collected in lithium heparin/EDTA, at (i) baseline (before starting probiotic administration), (ii) at the end of probiotic treatment (at 4 weeks), and (iii) at 4 weeks after discontinuation of probiotic intake. From 2.5 ml of blood, plasma was separated and stored at -70 degree centigrade. The remaining heparinized blood was used for whole blood culture and for measurement of frequencies of Th17 and Treg cells.

Heparinized blood was used and anti-CD28 (1 ug/ml) for stimulation of T cells and lipopolysaccharide for stimulation of macrophages, in separate wells. Culture supernatants were harvested after 72 hours and stored at -70 degree centigrade. Levels of cytokines (TNF-alpha, IL-10, IFN-gamma, IL-12p70, IL-6 and IL-4) were measured in culture supernatant and plasma using sandwich ELISAs.

Th1, Th2 and Th17 frequencies were determined by stimulation of whole blood with PMA and ionomycin, followed by staining of cells for CD4 and intracellular IFN, IL-4 and IL-1L-17. For Treg enumeration, dual staining for CD4 and Fox-P3 was done.

Ethics considerations The study involves administration of probiotics to healthy subjects. However, these contain bacteria that are a part of the normal gut flora in healthy persons and hence free of any adverse events. In fact, several healthy persons consume these as 'health supplements'. Hence, the administration of these agents should not carry more than minimal risk. The only specimens proposed to be collected are stool specimens and small volumes of blood. No clinical outcomes was collected.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date December 2015
Est. primary completion date November 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- healthy

- non-pregnant women

Exclusion Criteria:

(i) a systemic (diabetes, autoimmune disease, cancer), gastrointestinal or liver disease that is known to be associated with alteration in intestinal microbiota, (ii) obesity or malnutrition (body mass index of <18.5 or >25 Kg/m2), (iii) history of taking an anti-microbial agent, probiotic, or a drug that suppresses gastric acid or alters gastrointestinal motility, in the previous 6 weeks, (iv) any inter-current illness in the last 8 weeks, or (v) a recent change in dietary or bowel habits

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Probiotic (VSL#3)
Each subject provided morning stool and venous blood ubes) specimens at three time-points, i.e. at baseline (before probiotic administration), after probiotic administration (VSL#3®, one capsule twice a day) for 4 weeks, and at 4 weeks after stopping the probiotic intake. Each capsule contained approximately 112.5 billion live freeze-dried bacteria (a mixture of eight species -- Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii), which had been stored at 2-4ºC till ingestion.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Sanjay Gandhi Postgraduate Institute of Medical Sciences Indian Council of Medical Research

Outcome

Type Measure Description Time frame Safety issue
Primary Profile of gut flora among healthy Indian women To determine the profile of gut flora (% abundance of various bacterial phyla, families, genera and species) in healthy Indian women, using a metagenomic technique (sequencing of V3 region of 16S ribosomal RNA). Baseline
Primary Effect of probiotic preparation on gut-flora profile To determine the effect of administration of a probiotic preparation for a 4-week period on the profile of gut flora in healthy Indian women. 4 weeks of probiotics administration
Primary Effect of probiotic on immune responses To assess the effect of probiotic administration on immune responses, and the persistence of such changes on discontinuation of probiotic administration 4 weeks of probiotics administration
Secondary Persistence of changes, if any, in gut flora after probiotic discontinuation To determine whether the changes in gut flora after probiotic administration persist after discontinuation of such administration (at 4 weeks after such discontinuation) 4 weeks of discontinuation of probiotics administration
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Recruiting NCT06323642 - Role of Probiotics as Adjunct Therapy Along With Standard Care in Decreasing Hospital Stay and Improving Symptoms in Pediatric Patients Admitted With Severe Pneumonia N/A
Completed NCT03556631 - Effect of Live Combined Bifidobacterium and Lactobacillus on Glycemic Control and Other Outcomes in Type 1 Diabetes Phase 4
Completed NCT04043000 - Super 13 Pro & Prebiotics on the Human Intestinal Microflora N/A
Completed NCT04289337 - Double-blind Clinical Trials of Probiotic Products in Oral Health. N/A
Not yet recruiting NCT03967301 - Prevention and Decolonization of Multidrug-resistant Bacteria With Probiotics N/A
Completed NCT02207140 - Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly Phase 0
Completed NCT01201577 - Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals Phase 1
Not yet recruiting NCT06063226 - Clinical and Microbiological Aspects of Probiotics in Non-surgical Periodontal Therapy. N/A
Recruiting NCT05588674 - The Effect of Probiotics on Exercise Performance and Recovery N/A
Completed NCT05798689 - Use of a Selected Mixture of Probiotic Strains for Degrading Gluten During Digestion N/A
Completed NCT03167593 - Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65. Phase 2
Completed NCT05073393 - Effect of Probiotics on Oral Homeostasis During Sugar Stress N/A
Completed NCT02971787 - Salt Intake and Lactobacillus Abundance N/A
Recruiting NCT02005003 - Cognitive and Metabolic Effects of a Probiotic Supplement N/A
Recruiting NCT05657730 - Study the Effect of Water Kefir Consumption on the Gut Microbiome in Healthy Adults N/A
Completed NCT03499184 - Adjunctive Probiotics in Chronic Periodontitis N/A
Enrolling by invitation NCT04527055 - The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication Phase 4
Recruiting NCT05337670 - Probiotics Regulates Skin Care in Children N/A
Recruiting NCT05005611 - Probiotics Regulates Skin Care in Children N/A